Q1 EPS Forecast for Beam Therapeutics Boosted by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at Leerink Partnrs upped their Q1 2025 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.20) per share for the quarter, up from their prior estimate of ($1.26). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.23) EPS, Q3 2025 earnings at ($1.22) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.89) EPS and FY2026 earnings at ($5.08) EPS.

A number of other research firms also recently weighed in on BEAM. Royal Bank of Canada upped their target price on Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 26th. Guggenheim reiterated a “buy” rating and set a $78.00 target price on shares of Beam Therapeutics in a report on Thursday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Beam Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Beam Therapeutics in a report on Monday, March 10th. Finally, Wedbush reiterated an “outperform” rating and set a $57.00 target price on shares of Beam Therapeutics in a report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $50.82.

Beam Therapeutics Price Performance

Shares of NASDAQ:BEAM opened at $22.87 on Thursday. Beam Therapeutics has a 1 year low of $20.84 and a 1 year high of $36.75. The company has a market cap of $2.28 billion, a PE ratio of -12.99 and a beta of 1.91. The stock’s 50-day moving average is $26.82 and its 200 day moving average is $25.93.

Beam Therapeutics (NASDAQ:BEAM) last released its earnings results on Tuesday, February 25th. The company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.16. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company had revenue of $30.00 million during the quarter, compared to analyst estimates of $16.47 million. During the same quarter in the previous year, the company posted $1.73 EPS. Beam Therapeutics’s revenue for the quarter was down 90.5% on a year-over-year basis.

Insiders Place Their Bets

In other news, insider Christine Bellon sold 1,241 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $24.68, for a total transaction of $30,627.88. Following the completion of the transaction, the insider now owns 102,968 shares in the company, valued at $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John M. Evans sold 30,000 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the transaction, the chief executive officer now owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. The trade was a 3.20 % decrease in their position. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by company insiders.

Institutional Trading of Beam Therapeutics

Several institutional investors have recently added to or reduced their stakes in BEAM. Wealthfront Advisers LLC bought a new stake in Beam Therapeutics in the fourth quarter worth about $41,000. GF Fund Management CO. LTD. bought a new stake in Beam Therapeutics in the fourth quarter worth about $43,000. Sterling Capital Management LLC lifted its stake in Beam Therapeutics by 816.0% in the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company’s stock worth $60,000 after purchasing an additional 2,146 shares during the last quarter. KBC Group NV raised its stake in shares of Beam Therapeutics by 103.2% during the fourth quarter. KBC Group NV now owns 4,143 shares of the company’s stock valued at $103,000 after acquiring an additional 2,104 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Beam Therapeutics by 36.3% during the fourth quarter. Blue Trust Inc. now owns 4,274 shares of the company’s stock valued at $105,000 after acquiring an additional 1,139 shares in the last quarter. Institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.